Trigeminal neuralgia (TN), a classical neuropathic pain state, is a time-honored diagnosis and a well characterized condition with a variety of possible etiological backgrounds. It has recently been classified and described in detail by the International Headache Society (http://www.ihs-headache.org) and in a consensus report by the European Academy of Neurology.1 Three diagnostic subgroups have been identified: classical, symptomatic and idiopathic TN. A common denominator in the clinical phenomenology, initially described already as early as in the 2th century CE (see Nurmikko and Eldridge2) is the paroxysmal pain component, usually only a few seconds in duration, not infrequently accompanied by a “tic” (i.e. a brief facial twitch movement) on the affected side. In addition, some patients report an “atypical” concomitant continuous or near-continuous ongoing pain on which the paroxysms are superimposed. These sufferers always have an initial history of paroxysmal pain only. The majority of patients also report trigger zones, extra- or intraorally, where mild tactile stimuli may induce a painful tic. Not infrequently a period of refractoriness will be evident so that new triggers fail to induce a pain paroxysm for a short period of time. If, for example, chewing, intraoral stimuli or swallowing trigger an attack, the refractory period can be used to literally shove food down the gastrointestinal tract, before sensitivity returns.

Explorations in animal models are used for the understanding of disease mechanisms potentially translatable into development of new therapies for patients. In neurobiology, the degree to which these models are successful in mimicking the disease that is investigated varies, and is frequently not satisfactory (e.g. see literature3–5). Based on these considerations we conclude that from a scientific as well as an ethical standpoint, animal experiments in pain research should be subjected to rigorous experimental design. Keeping this in mind, it is conspicuously disturbing to note that according to Pub Med, between 2016 and 2019 at least 21 articles have been published where the authors claim that they are using an animal model of TN (e.g. see previous works6–11). Among those are articles published in Molecular Pain.

These reports, performed on a rodent model that is supposed to reflect TN in humans, are to us a long overdue wakeup call that must not pass unnoticed. The model used is a mechanical injury to the infraorbital nerve, the major branch of the n.V:2, which is said to induce the specific painful symptoms and signs of TN in all animals included. It is far from clear to the reader why TN is brought forward in these studies, since the same injury in other work is postulated to induce a painful trigeminal neuropathy (for references, see e.g. Ding et al.12), a condition significantly different from TN not only from the clinical phenomenology perspective,13 but also regarding evidence-based treatment.14

The molecular mechanisms behind TN are still unknown, and the quest for it constitutes a major challenge for neurobiology and neurology. Some 25 years ago, Devor and colleagues based on electrophysiological data and clinical observations suggested that the mechanism behind TN characteristics in some specific etiologies such as triggering, amplification and discontinuation of pain attacks is related to altered (increased) excitability of trigeminal ganglion neurons (the ignition hypothesis, see Rappaport and Devor15 and Devor et al.16). This hyperexcitability would be a sequel of nerve injury and demyelination, coming from e.g. compression of the trigeminal nerve root by a blood vessel close to the brainstem. Accordingly, the situation is improved in some, but not all, patients with this...
etiology who undergo surgical intervention to decompress a nerve root. Some patients with various etiologies of TN also benefit from glycerol injection, thermocoagulation or balloon compression of the trigeminal ganglion, alternatively from gamma irradiation in the trigeminal root entry zone.17

Experimental damage to the infraorbital nerve as a model for TN is indeed questionable. When this nerve was injured in the rat using cobra venom, it was claimed that significant changes in exploratory, resting, face-grooming, and head-shake behaviors appeared after surgery.18 These alterations, which were ascribed to demyelination in the infraorbital nerve, do not mimic the clinical features of human TN as noted above. A couple of studies have actually followed the lead regarding mechanical pressure on the trigeminal root as cause for TN.19,20 In one, crystals of a superabsorbent polymer were placed next to the trigeminal nerve root of rats, thereby causing ongoing compression of the trigeminal nerve root.20 However, the subsequent testing demonstrated only increased sensitivity to mechanical stimuli in the face but spontaneous paroxysmal attacks (i.e. the hallmark of TN) were not reported. Thus, it was not a model of TN, although this was stated even in the title of the paper.

In conclusion, we urge researchers in the field, and certainly referees of data that is submitted for review, not to take TN lightly. As far as we know, there is no animal model that even remotely meet the criteria for a TN model. TN is a devastating disease for those patients who do not get relief from evidence-based interventions, such as administration of carbamazepine/oxybarbazine,17 or from neurosurgical strategies such as those mentioned above. The remaining sufferers need serious innovative attempts in neuroscience and neurology to receive help.

Acknowledgment
We thank professor Marshall Devor for valuable comments.

Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The author(s) received no financial support for the research, authorship, and/or publication of this article.

ORCID iD
Kaj Fried https://orcid.org/0000-0002-9997-7078

References
1. Bendtsen L, Zakrzewska JM, Abbott J, Braschinsky M, Di Stefano G, Donnet A, Eide PK, Leal PRL, Maarbjerg S, May A, Nurminikko T, Obermann M, Jensen TS, Cruccu G. European academy of neurology guideline on trigeminal neuralgia. *Eur J Neurol* 2019; 26: 831–849.
2. Nurminikko TJ, Eldridge PR. Trigeminal neuralgia—pathophysiology, diagnosis and current treatment. *Br J Anaesth* 2001; 87: 117–132.
3. Mergenthaler P, Meisel A. Do stroke models model stroke? *Dis Model Mech* 2012; 5: 718–725.
4. Spanagel R. Animal models of addiction. *Dialogues Clin Neurosci* 2017; 19: 247–258.
5. Dawson TM, Golde TE, Touroune CL. Animal models of neurodegenerative diseases. *Nat Neurosci* 2018; 21: 1370–1379.
6. Yang YJ, Hu L, Xiu XP, Jiang CY, Miao C, Yang CQ, Yuan M, Wang L. Resveratrol suppresses glial activation and alleviates trigeminal neuralgia via activation of AMPK. *J Neuroinflamm* 2016; 13: 84.
7. Zhang Y, Su Q, Lian Y, Chen Y. Botulinum toxin type A reduces the expression of transient receptor potential melastatin 3 and transient receptor potential vanilloid type 4 in the trigeminal subnucleus caudalis of a rat model of trigeminal neuralgia. *Neuroreport* 2019; 30: 735–740.
8. De Oliveira CL, Medeiros LF, De Souza VS, Lopes BC, De Oliveira FF, Marques LX, Da Silva Torres IL, De Souza A. Low-dose naltrexone reverses facial mechanical allodynia in a rat model of trigeminal neuralgia. *Neurosci Lett* 2020; 736: 135248.
9. Fu J, Mu G, Qiu L, Zhao J, Ou C. Cehua Ou C. c-Abl-p38 signaling pathway mediates dopamine neuron loss in trigeminal neuralgia. *Mol Pain* 2020; 16: 1744806920930855.
10. Li Y, Jiao H, Ren W, Ren F. TRESK alleviates trigeminal neuralgia induced by infraorbital nerve chronic constriction injury in rats. *Mol Pain* 2019; 15: 1744806919882511.
11. Wang L, Long M, Wang M, Peng S, Chen G, Zhou J, Ou C. Trigeminal neuralgia causes neurodegeneration in rats associated with upregulation of the CD95/CD95L pathway. *Mol Pain* 2020; 16: 1744806920908092.
12. Ding W, You Z, Shen S, Yang J, Lim G, Doheny J, Chen L, Zhu A, Mao J. An improved rodent model of trigeminal neuropathic pain by unilateral chronic constriction injury of distal infraorbital nerve (dIoN-CCI). *J Pain* 2017; 18: 899–907.
13. Cruccu G, Finnerup NB, Jensen TS, Scholz J, Sindou M, Svensson P, Treede RD, Zakrzewska JM, Nurminiko T. Trigeminal neuralgia: new classification and diagnostic grading for practice and research. *Neurology* 2016; 87: 220–228.
14. Finnerup NB, Attal N, Haroutounian S, McNicoll E, Baron R, Dworkin RH, Gilron I, Haanpää M, Hansson P, Jensen TS, Kamerman PR, Lund K, Moore A, Raja SN, Rice ASC, Rowbotham M, Sena E, Siddall P, Smith BH, Wallace M. Pharmacotherapy for neuropathic pain in adults: systematic review, meta-analysis and updated NeuPSIG recommendations. *Lancet Neurol* 2015; 14: 162–173.
15. Rappaport ZH, Devor M. Trigeminal neuralgia: the role of self-sustaining discharge in the trigeminal ganglion. *Pain* 1994; 56: 127–138.
16. Devor M, Amir R, Rappaport ZH. Pathophysiology of trigeminal neuralgia: the ignition hypothesis. Clin J Pain 2002; 18: 4–13.
17. Maarbjerg S, Di Stefano G, Bendtsen L, Cruccu G. Trigeminal neuralgia - diagnosis and treatment. Cephalalgia 2017; 37: 648–657.
18. Zhao QQ, Qian XY, An JX, Liu CC, Fang QW, Wang Y, Jiang YD, Cope DK, Williams JP. Rat model of trigeminal neuralgia using cobra venom mimics the electron microscopy, behavioral, and anticonvulsant drug responses seen in patients. Pain Physician 2015; 18: E1083–E1090.
19. Luo D, Lin R, Luo L, Li Q, Chen T, Qiu R, Li Y. Glial plasticity in the trigeminal root entry zone of a rat trigeminal neuralgia animal model. Neurochem Res 2019; 44: 1893–1902.
20. Yeomans DC, Klukinov M. A rodent model of trigeminal neuralgia. Methods Mol Biol 2012; 851: 121–131.